59例BCRABL阳性急性淋巴细胞白血病的临床特征及治疗转归.pdf

·512· SouthMed 南方医科大学学报U Univ) 2009；29(3) 59例BCR／ABL阳性急性淋巴细胞白血病的临床特征及治疗转归 刘志，刘晓力，杜庆锋，许娜，钟敏，宋兰林，易正山，刘启发，孟凡义，周淑芸(南方医科大学南方医院血液 科，广东广州510515) 疗效的相关预后因素。方法我院2001年1月至2008年5月荧光原位杂交检查确诊为原发BCR／ABL+-ALL59例．经 VDLP±Ara．C方案诱导化疗，化疗不缓解者或准备移植者给予伊马替尼治疗，其中接受伊马替尼联合治疗17例．行异 期短，伊马替尼联合治疗和allo．HSCT均可延长BCR／ABL+．ALL的生存期。 关键词：急性淋巴细胞白血病；BCR／ABL；伊马替尼；异基因造血干细胞移植 中图分类号：R733．7文献标识码：A 文章编号：1673-4254(2009)03．0512．04 Clinicalcharacteristicsandoutcomesof59 withacute leukemia patients lymphoblastic forBCR／ABL positive LIU删，LILJXiao—li，DUQing-feng，XUNa，ZHONGMin，SONGLan-lin，YIZheng-shan，L1UQi-fa，MENGFan-yi，ZHOUShu-yun of Medical 51051 DepartmentHematology，NanfangHospital，SouthernUniversity，Guangzhou5，China To theclinicalcharacteristicsandOHtcomes acute leukemia Abstraet：Objecfivestudy ofBCR／ABL-positivelymphoblastic screenthe factorsforBCR／ABL+．ALL．MethodsFrom 200l to 2008．59 (BCR^墟L+．ALL)andprognostic January May of32 from3to69 the ofBCR，ABL+．ALLbvfluorescenceinsitu patients(medianage yearsranging years)withdiagnosis wimVDLP±Ara．C whofailed to receivedinduction to the hybridization chemotherapy regimen．Thepatients respond received consolidation with 7 chemotherapysubsequent chemotherapyimatinib(400·800mg／day)(1 cases)orallogeneie stemeell Ofthe59 achieved hematopoietictransplantation(allo—H